The HbA1c Advanced Assay from Beckman Coulter offers Physicians a higher accuracy in diagnosis for patients with Diabetes

Brea, California (ots/PRNewswire) – Beckman Coulter, a global leader in clinical diagnostics, announced today the fully-automatic hemoglobin A1c (HbA1c), Advanced Assay is the newest addition to its comprehensive offer of chemical Assays. With this new Assay medium to large laboratories allow Doctors to state of the art precision and accuracy in the diagnosis of Diabetes, a long-term Monitoring of the glucose level and the identification of patients who may be at risk for the development of Diabetes.

New Assay receives CE-marking and U.S. FDA 501(k) approval

The HbA1c Advanced Assay, the 700 is now also available for the DxC is available, offers a higher level of laboratory efficiency without the need for manual sample preparation. Thanks to the addition of the new Assay, laboratories can integrate the whole blood analysis in your existing Routine and STAT samples, and processing times are shortened.

„The early detection of Diabetes increases the chances of a patient to avoid harmful and costly complications,“ said Puneet Sarin, Senior Vice President, clinical chemistry and Immunoassay, Beckman Coulter. „50 % of people with Diabetes are not diagnosed, therefore, it is urgently needed to identify people with this disease and to provide appropriate. We have developed the HbA1c Advanced Assay to meet these needs and to deliver effective clinical results, the Doctors in the diagnosis and Monitoring of Diabetes need“.

Today, an estimated 425 million people worldwide have Diabetes. This value corresponds to 8.8% of adults aged 20 to 79 years. If the current growth trend continues, will suffer until the year 2045 629 million people in this group of the population to this disease.

The determination of HbA1c in the blood is an important means for the diagnosis of Diabetes and to Monitor the effectiveness of dietary changes and other therapies that are used in the context of diabetes management. In recent validation studies of the new HbA1c Advanced Assay showed a first-class Six-Sigma Performance. A high Sigma-metric leads to fewer analysis errors and questionable test results worthy of.

The new HbA1c Advanced Assay from Beckman Coulter demonstrates the company’s commitment for faster processes in the healthcare system by providing clinical partners with an impressive range of important solutions that deal with the most common and most expensive health risks. The new Assay Kit is a U.S. FDA 501(k) approval and CE recently received marking and is suitable for use in the recently launched chemistry analyzer DxC 700 AU from Beckman Coulter.

For more information on the comprehensive range of chemical Assays from Beckman Coulter or other chemistry and Immunoassay solutions, please visit https://BeckmanCoulter.com/hemoglobin-a1c.

Information about Beckman Coulter Diagnostics

Beckman Coulter Diagnostics, supports Physicians and laboratory professionals at any time for the improvement of patient care with accurate and necessary diagnostic information. With its rich 80-year history of Beckman Coulter is a strong Partner for healthcare organizations. Our scalable tools, comprehensive diagnostic tests and business services are highly valued by hospitals, laboratories and facilities of intensive care medicine around the world. We support the Mission of our customers, committed to continuous improvement and high quality patient care. We are convinced that an improvement in the efficiency and clinical results of patients benefit and we can bring health care for every human being.

© 2019 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized Logo, and the herein mentioned product – and service trademarks of Beckman Coulter are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Logo
https://mma.prnewswire.com/media/525815/Beckman_Coulter_Logo.jpg

Roslyn Whitehurst
Beckman Coulter Public Relations
714-961-4391 > rwhitehurst@beckman.com